Absence of Alzheimer disease neuropathologic changes in eyes of subjects with Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 76, Issue 5, 2017, Pages 376-383

  Williams, Erik A ^a   McGuone, Declan ^a   Frosch, Matthew P ^a   Hyman, Bradley T ^a   Laver, Nora ^b   Stemmer Rachamimov, Anat ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Biomarkers; Ocular changes

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; UBIQUITIN; NERVE PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUSEN; EYE DISEASE; FEMALE; GLAUCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATOPATHY; MACULAR DEGENERATION; MALE; NEUROPATHOLOGY; OPEN ANGLE GLAUCOMA; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; RETINA TEAR; BRAIN; CELL INCLUSION; EYE; GENETICS; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUTOPSY; BRAIN; EYE; FEMALE; GLAUCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; MACULAR DEGENERATION; MALE; NERVE TISSUE PROTEINS;

EID: 85017152069     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlx020     Document Type: Article

References (36)

1. Hinton DR, Sadun AA, Blanks JC, et al. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 1986;315:485-7
2. Blanks JC, Hinton DR, Sadun AA, et al. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res 1989;501:364-72
3. Kesler A, Vakhapova V, Korczyn AD, et al. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg 2011;113:523-6
4. Ascaso FJ, Cruz N, Modrego PJ, et al. Retinal alterations in mild cognitive impairment and Alzheimer's disease: An optical coherence tomography study. J Neurol 2014;261:1522-30
5. Cheung CY, Ong YT, Hilal S, et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2015;45:45-56
6. Coppola G, Di Renzo A, Ziccardi L, et al. Optical Coherence tomography in alzheimer's disease: A meta-analysis. PLoS One 2015;10:e0134750
7. Pillai JA, Bermel R, Bonner-Jackson A, et al. Retinal nerve fiber layer thinning in Alzheimer's disease: A case-control study in comparison to normal aging, Parkinson's disease, and non-Alzheimer's dementia. Am J Alzheimers Dis Other Demen 2016;31:430-6
8. Reed BT, Behar-Cohen F, Krantic S. Seeing early signs of Alzheimer's Disease through the lens of the eye. Curr Alzheimer Res 2017;14:6-17
9. Williams MA, McGowan AJ, Cardwell CR, et al. Retinal microvascular network attenuation in Alzheimer's disease. Alzheimers Dement (Amst) 2015;1:229-35
10. Frost S, Guymer R, Aung KZ, et al. Alzheimer's disease and the early signs of age-related macular degeneration. Curr Alzheimer Res 2016;13: 1259-66
11. Liu B, Rasool S, Yang Z, et al. Amyloid-peptide vaccinations reduce bamyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol 2009;175: 2099-110
12. Ning A, Cui J, To E, et al. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 2008;49:5136-43
13. Perez SE, Lumayag S, Kovacs B, et al. Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 2009;50:793-800
14. Tan Z, Ge J. Amyloid-beta, the retina, and mouse models of Alzheimer disease. Am J Pathol 2010;176:2055
15. Zhao H, Chang R, Che H, et al. Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer's disease transgenic mouse. Neurosci Lett 2013;551:12-6
16. More SS, Vince R. Hyperspectral imaging signatures detect amyloidopathy in Alzheimer's mouse retina well before onset of cognitive decline. ACS Chem Neurosci 2015;6:306-15
17. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011;54 Suppl: 1:S204-17
18. Heaton GR, Davis BM, Turner LA, et al. Ocular biomarkers of Alzheimer's disease. Cent Nerv Syst Agents Med Chem 2015;15:117-25
19. Lóffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 1995;36:24-31
20. Leger F, Fernagut PO, Canron MH, et al. Protein aggregation in the aging retina. J Neuropathol Exp Neurol 2011;70:63-8
21. Schón C, Hoffmann NA, Ochs SM, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One 2012;7: e53547
22. Ho CY, Troncoso JC, Knox D, et al. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol 2014;24:25-32
23. Goldstein LE, Muffat JA, Cherny RA, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 2003;361:1258-65
24. Moncaster JA, Pineda R, Moir RD, et al. Alzheimer's disease amyloidbeta links lens and brain pathology in Down syndrome. PLoS One 2010; 5:e10659
25. Michael R, Rosandíc J, Montenegro GA, et al. Absence of b-amyloid in cortical cataracts of donors with and without Alzheimer's disease. Exp Eye Res 2013;106:5-13
26. Tian T, Zhang B, Jia Y, et al. Promise and challenge: the lens model as a biomarker for early diagnosis of Alzheimer's disease. Dis Markers 2014; 2014:826503
27. Thal DR, Rúb U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
28. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
29. Mirra SS, Heyman A, et al. The Consortium to establish a registry for Alzheimer disease (CERAD). Part II Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
30. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012; 123:1-11
31. Hyman BT, Phelps CH, Beach TG, et al. National institute on aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13
32. Nelson PT, Alafuzoff Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012;71:362-81
33. Bringmann A, Pannicke T, Grosche J, et al. Mú ller cells in the healthy and diseased retina. Prog Retin Eye Res 2006;25:397-424
34. Li L, Luo J, Chen D, et al. BACE1 in the retina: A sensitive biomarker for monitoring early pathological changes in Alzheimer's disease. Neural Regen Res 2016;11:447-53
35. Frost S, Kanagasingam Y, Sohrabi H, et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transl Psychiatry 2013;2:e233
36. Ho WL, Leung Y, Tsang AW, et al. Review: Tauopathy in the retina and optic nerve: Does it shadow pathological changes in the brain? Mol Vis 2012;18:2700-10